pyrroles has been researched along with carboplatin in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 23 (88.46) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Larsson, C; Svensson, K | 1 |
| Buchdunger, E; García-Echeverría, C; Hofmann, F; Krystal, GW; Litz, J; Warshamana-Greene, GS | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Cao, Q; Chen, Q; Cheng, C; Jin, Y; Pan, J; Verstovsek, S | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| de Vos, J; de Vos, P; Noorman, E; Ramos Vega, S | 1 |
| An, Y; Chen, J; Hou, J; Lan, T; Li, X; Liu, J; Pan, Y; Tie, L; Zhang, J | 1 |
| Berger, MS; Blakely, J; Chiappori, AA; Chu, QS; Moezi, MM; Ross, HJ; Salgia, R; Schnyder, J; Schreeder, MT; Stephenson, JJ; Subramaniam, DS | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Adjei, AA; Belani, CP; Chow, LQ; Dy, GK; Fortin, C; Gupta, A; Jonker, DI; Laurie, SA; Nicholas, G; Park, JS; Patricia, D; Sbar, EI; Zhang, S | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Bright, SA; Butini, S; Campiani, G; Carroll, E; Lennon, JC; O'Meara, A; Williams, DC; Zisterer, DM | 1 |
| Albert, I; Ao-Baslock, A; Berger, MS; Blakely, LJ; Kazarnowicz, A; Kovacs, P; Langer, CJ; Moezi, MM; Pajkos, G; Pathak, AK; Ross, HJ; Schnyder, J; Schreeder, MT; Somfay, A; Zatloukal, P | 1 |
| Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE | 1 |
| Bailey, DB; Borgatti, A; Clifford, CA; Crawford-Jakubiak, M; Cronin, KL; Gardner, HL; Gill, VL; Henry, CJ; Klein, MK; Locke, J; London, CA; Mathie, T; Northrup, NC; Pennell, ML; Phillips, B; Portela, R; Post, G; Rosenberg, MP; Ruslander, DM; Stingle, N; Thamm, DH; Vail, DM; Williams, LE; Wilson-Robles, H | 1 |
| Hainsworth, JD; Midha, R; Peacock, NW; Priego, VM; Shastry, M; Shipley, DL; Yardley, DA | 1 |
| Burke, NS; Court, MH; Dassanayake, S; Fidel, J; Lewis, RS; Mealey, KL | 1 |
| Bogart, JA; Crawford, J; Gu, L; Pang, HH; Ready, NE; Salama, JK; Schild, SE; Vokes, EE; Wang, X | 1 |
| Butini, S; Campiani, G; Lennon, JC; O'Meara, A; Williams, DC; Zisterer, DM | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Clarke, D; Gieger, TL; Hallman, B; Johannes, C; Nettifee-Osborne, J; Nolan, MW; Williams, LE | 1 |
| Higginbotham, ML; Hocker, SE; Wouda, RM | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Ahn, S; Cao, S; O'Shaughnessy, J; Tan, AR; Yi, JS | 1 |
1 review(s) available for pyrroles and carboplatin
| Article | Year |
|---|---|
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
17 trial(s) available for pyrroles and carboplatin
| Article | Year |
|---|---|
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System; Drug Administration Schedule; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Small Cell Lung Carcinoma | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperidines; Pyrroles; Treatment Outcome; Triazines | 2013 |
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Young Adult | 2013 |
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2015 |
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
Topics: Administration, Metronomic; Amputation, Surgical; Animals; Bone Neoplasms; Carboplatin; Cyclophosphamide; Diarrhea; Disease-Free Survival; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Indoles; Kaplan-Meier Estimate; Male; Neutropenia; Osteosarcoma; Piroxicam; Prospective Studies; Pyrroles; Regression Analysis; Treatment Outcome | 2015 |
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Pyrroles; Retrospective Studies; Small Cell Lung Carcinoma; Sunitinib | 2016 |
The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Indoles; Male; Matrix Metalloproteinase 9; Osteosarcoma; Pilot Projects; Pyrroles; Vascular Endothelial Growth Factor A | 2017 |
Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Topics: Animals; Carboplatin; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Indoles; Male; Neoplasms; Pyrroles | 2018 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Pyrimidines; Pyrroles; Triple Negative Breast Neoplasms | 2023 |
8 other study(ies) available for pyrroles and carboplatin
| Article | Year |
|---|---|
A protein kinase Cbeta inhibitor attenuates multidrug resistance of neuroblastoma cells.
Topics: Carboplatin; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Maleimides; Mesylates; Neuroblastoma; Paclitaxel; Peripheral Nervous System Neoplasms; Protein Kinase C; Pyrroles; Tumor Cells, Cultured; Vincristine | 2003 |
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Insulin-Like Growth Factor I; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Messenger; Vascular Endothelial Growth Factor A | 2005 |
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells.
Topics: Autophagy; Carboplatin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Humans; Indoles; Osteosarcoma; Pyrroles; Signal Transduction | 2010 |
Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Dog Diseases; Dogs; Drug Therapy, Combination; Frontal Sinus; Indoles; Male; Paranasal Sinus Neoplasms; Piroxicam; Pyrroles; Receptor Protein-Tyrosine Kinases | 2012 |
Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Xenograft Model Antitumor Assays | 2012 |
The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Neuroblastoma; Oxazepines; Pyrroles; Up-Regulation | 2014 |
Comparison of chemotherapeutic drug resistance in cells transfected with canine ABCG2 or feline ABCG2.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carboplatin; Cats; Cell Survival; Dogs; Doxorubicin; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Indoles; Mitoxantrone; Pyrroles; Transfection; Vincristine | 2017 |
Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells.
Topics: Acetyl-CoA Carboxylase; Acetylcysteine; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Carboplatin; Cell Line, Tumor; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Oxazepines; Phosphorylation; Pyrroles; Reactive Oxygen Species; Tubulin Modulators; Tumor Burden | 2016 |